
Opinion|Videos|November 20, 2026
When Does Barth Syndrome Get Worse? Stress & the Disease Timeline
Author(s)Hilary Vernon, MD, PhD , Majid Husain, MD
Dr. Vernon distinguishes Barth syndrome from other mitochondrial diseases: the cardiomyopathy-plus-neutropenia combination without neurologic involvement is unique.
Advertisement
Episodes in this series
Dr. Vernon distinguishes Barth syndrome from other mitochondrial diseases: the cardiomyopathy-plus-neutropenia combination without neurologic involvement is unique. She identifies metabolic stress periods that drive cardiac decompensation -- infantile feeding, adolescent growth spurts (delayed puberty at ages 17-18), and intercurrent viral infections -- and notes the unusual cardiac remodeling pattern where enlarged hearts may normalize and then re-dilate. Dr. Husain adds that viral cardiomyopathy misdiagnosis likely accounts for a subset of underdiagnosed Barth cases.
Advertisement
Related to this article

William Roth, MD, assistant professor of neurology at the University of Chicago, discusses the role of the gut microbiome in stroke risk and recovery and emerging strategies to modify it in the acute and preventive settings.

Three randomized trials pooled in a new systematic review found that thrombectomy did not improve 90-day functional outcomes after medium or distal vessel occlusion stroke, while increasing bleeding risk.

In a phase 2a trial presented at CTAD 2026, neflamapimod kept plasma NfL stable in nonfluent variant primary progressive aphasia over 24 weeks.

Brian Lin, PhD, senior director of research at the Muscular Dystrophy Association (MDA), discussed the sessions he is most excited about at the 2027 MDA Clinical and Scientific Conference.

The FDA approved oral venglustat for neurological manifestations of type 3 Gaucher disease after the phase 3 LEAP2MONO trial showed superiority over imiglucerase on a combined ataxia and cognition measure.

A new phase 2b trial, SPINOZA, will test whether obicetrapib, a cholesteryl ester transfer protein (CETP) inhibitor, slows Alzheimer disease biomarker progression in APOE-stratified, cognitively unimpaired adults.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Cemdisiran as New Treatment for Generalized Myasthenia Gravis
2
FDA Approves Venglustat as First Therapy for Neurological Manifestations of Type 3 Gaucher Disease
3
Phase 2 SPINOZA Trial to Test CETP Inhibitor Obicetrapib in APOE-Stratified Preclinical Alzheimer Disease
4
ALS Prevention, Gene Therapy, and Newborn Screening at MDA 2027
5


